Aim: To assess antigenic composition consistency and serological characteristics of domestic acellular pertussis vaccine.
Materials And Methods: Amount of pertussis toxin, filamentous hemagglutinin, agglutinogens types 1, 2, and 3 in experimental batches of vaccine was measured by enzyme immunoassay. Levels of antibodies to aforementioned antigens as well as to lipopolysaccbaride in serum samples obtained from patients with pertussis and healthy vaccinated children were measured by the same method. The amount of lypopolysaccharide was determined by LAL test.
Results: Studied batches of vaccine were standard on amount of all protein antigens as well as lipopolysaccharide. Spectrum of antibodies to vaccine components in serum samples from patients with pertussis and healthy vaccinated children included antibodies to individual antigens: pertussis toxin, filamentous hemagglutinin, lipopolysaccharide, agglutinogens types 1, 2, and 3.
Conclusion: Developed technology for manufacturing acellular pertussis vaccine allows to consistently produce preparations with standard amount of all components. Vaccine components interact with antibodies to wide spectrum of B. pertussis antigens.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of anti-Pertussis antibody levels in Iranian infants and children: Is it time to include booster acellular Pertussis Vaccines in the immunization schedule?
Vaccine
January 2025
Pediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Introduction: The prevalence of anti-pertussis antibodies among infants and children in Iran has not been thoroughly investigated. Given that recommendations for booster vaccines are based on national disease epidemiology, we aimed to evaluate the seroprevalence of pertussis antibodies among infants and children in an Iranian referral hospital.
Materials And Methods: A total of 1012 infants and children were included in the study.
Vaccination against measles-mumps-rubella and rates of non-targeted infectious disease hospitalisations: Nationwide register-based cohort studies in Denmark, Finland, Norway, and Sweden.
J Infect
January 2025
Bandim Health Project, Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Objectives: To investigate if receipt of measles-mumps-rubella (MMR) vaccine following the third dose of diphtheria-tetanus-acellular pertussis (DTaP3) is associated with reduced rates of non-targeted infectious disease hospitalisations.
Methods: Register based cohort study following 1,397,027 children born in Denmark, Finland, Norway, and Sweden until 2 years of age. Rates of infectious disease hospitalisations with minimum one overnight stay according to time-varying vaccination status were compared using Cox proportional hazards regression analysis with age as the underlying timescale and including multiple covariates.
Genomic epidemiology and evolution of under the vaccination pressure of acellular vaccines in Beijing, China, 2020-2023.
Emerg Microbes Infect
December 2025
Department of Immunization and Prevention, Beijing Chaoyang District Center for Disease Control and Prevention, Beijing, People's Republic of China.
Article Synopsis
- Pertussis is seeing a global increase, particularly in China post-COVID-19, despite vaccination efforts.
- A study analyzed 60 strains from Beijing from 2020-2023, revealing genetic changes and increased resistance to the antibiotic erythromycin among the isolates.
- The dominant genotype shifted significantly from those prior to 2019 due to vaccine pressure, highlighting the necessity for ongoing monitoring and updates to vaccination strategies.
Safety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda.
Lancet Glob Health
January 2025
Centre for Neonatal and Paediatric Infection and Vaccine Institute, City St George's, University of London, London, UK; Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda; UK Health Security Agency, Salisbury, UK.
Article Synopsis
- The study investigates the safety and immunogenicity of a TdaP vaccine for pregnant women living with HIV, aiming to protect infants from severe pertussis disease.
- Conducted in Uganda, the trial randomly assigned 181 women (HIV-positive and HIV-negative) to receive either the TdaP or Td vaccine, evaluating immune responses in infants post-delivery.
- Findings will provide valuable insights into the vaccine's effectiveness and safety for this specific population, contributing to better health outcomes for mothers and their babies.
The feasibility of utilizing district health information system and short message services on decreasing child immunization dropout and increasing vaccination timeliness in Duhok Governorate.
Public Health
January 2025
School of Science and Engineering, University of Kurdistan Hewlêr (UKH), Erbil City, Iraq. Electronic address:
Objectives: To develop a customized individual-based electronic immunization registry using the DHIS-2 platform and investigate its effectiveness combined with short message service reminders to decrease the child immunization dropout rate and improve vaccination timeliness in the Duhok Governorate.
Study Design: This was a quasi-experimental study.
Methods: The study included a preliminary pilot assessment examining deficiencies and requirements of the current paper-based immunization system, which informed the development of a tailored electronic immunization registry.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!